The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.
Sign Up to like & getrecommendations! Published in 2025 at "Future oncology"
DOI: 10.1080/14796694.2025.2475728
Abstract: With the ongoing discovery of various oncogenic driver mutations in metastatic non-small cell lung cancer (mNSCLC), a precision medicine approach has emerged, characterized by targeted therapies for select patient populations. Randomized controlled trials (RCT) remain… read more here.
Keywords: targeted therapies; real world; rare oncogenic; world evidence ... See more keywords